The Society for Immunotherapy of Cancer (SITC) 28th Annual Meeting
November 8-10, 2013
Gaylord National Hotel & Convention Center
National Harbor, MD
Program Organizers
Paolo Antonio Ascierto, MD - Instituto Nazionale Tumori-Fondazione ‘G. Pascale’
David H. Munn, MD - Georgia Regents University
A. Karolina Palucka, MD, PhD - Baylor Institute for Immunology Research
Paul M. Sondel, MD, PhD - University of Wisconsin
Program Summary
The SITC 28th Annual Meeting provided a multidisciplinary educational and interactive environment focused on improving the outcome for current and future patients with cancer by incorporating strategies based on basic and applied cancer immunotherapy. The meeting consisted of cutting-edge research presentations by experts in the field, both oral and poster abstract presentations and ample opportunity for structured and informal discussions, including important networking opportunities. In addition, the meeting included updates on major national and international initiatives coming from academia, government and industry, as well as important society projects.
Target Audience
The target audience for this program was basic and clinical investigators from academic institutions, industry and regulatory agencies, including clinicians, basic and translational researchers, graduate students, post-doctoral fellows, and allied health professionals involved in cancer research as well as pharmacists and payers, that wish to learn more about cancer immunology and immunotherapy, and its incorporation into current (and future) effective cancer treatment.
Presentations and video recordings are available based on permission from presenters.
#ClinicalTrials #Immunoscore #ColorectalCancer #HeadandNeckCancers #Neuroblastoma #ProstateCancer #PresentationSlides #AnnualMeeting #ImmuneCheckpointInhibitors #TherapeuticAntibodies #Vaccines #AlliedHealth #Clinician #Industry #Oncologist #Researcher #2013 #BreastCancers#ColonCancer #Melanoma #Non-SmallCellLungCancer #GastrointestinalCancers #OvarianCancer #RenalCellCarcinoma#AdoptiveCellTherapy #CombinationTherapy #Ipilimumab #Nivolumab